164221-12-9

Basic information

• Product Name: (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol
• Synonyms: (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol
• CAS NO: 164221-12-9
• Molecular Weight: 288.473
• Mol File: 164221-12-9.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol(164221-12-9)
• EPA Substance Registry System: (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol(164221-12-9)

Safety Data

• Hazardous Substances Data: 164221-12-9(Hazardous Substances Data)

Usage

General Description

(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol is a long-chain unsaturated alcohol with 20 carbon atoms and 5 double bonds, arranged in a zig-zag configuration. It is commonly known as icosa-5,8,11,14,17-pentaen-1-ol and is a member of the family of long-chain unsaturated alcohols. (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol is used in the production of various industrial products, including surfactants, lubricants, and plasticizers. It also has potential applications in the pharmaceutical and cosmetic industries. The presence of the multiple double bonds in the carbon chain gives this compound unique properties that make it suitable for various chemical and industrial processes.

Upstream product

• 10417-94-4 all cis-5,8,11,14,17-eicosapentaenoic acid 
• 2566-90-7 all-cis-4,7,10,13,16,19-docosahexaenoic acid methyl ester 
• 2734-47-6 (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-icosapentaenoic acid methyl ester 
• 86227-47-6 eicosapentaenoic acid ethyl ester 

Downstream Products

• 690223-81-5 [((5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenyl)sulfanyl]-benzene 
• 1192949-29-3 (all-Z)-5,8,11,14,17-eicosapentaen-1-yl di-methyl-phosphonate 
• 1316749-23-1 2-hydroxy-N-(2-(2-((5Z,8Z_,11Z_,14Z,17Z)-icosa-5_,8_,11,14,17-pentaen-1-yloxy)butanamido)ethyl)benzamide 
• 1316749-37-7 methyl 2-hydroxy-5-((2S)-2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)-4-methylpentanamido)benzoate 
• 1316749-40-2 2-hydroxy-5-((2S)-2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)-4-methylpentanamido)benzoic acid 
• 1316749-41-3 methyl 2-hydroxy-5-(((2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)ethoxy)carbonyl)amino)benzoate 
• 1316749-43-5 2-hydroxy-5-(((2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)ethoxy)carbonyl)amino)benzoic acid 
• 1316749-49-1 methyl 2-hydroxy-5-(3-(2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)ethyl)ureido)benzoate 
• 1316749-50-4 2-hydroxy-5-(3-(2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)ethyl)ureido)benzoic acid 
• 1316749-15-1 tert-butyl 2-((2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoyl)oxy)benzoate 
• 1316749-16-2 2-((2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoyl)oxy)benzoic acid 
• 1253909-48-6 (4S,5R)-3-((S)-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoyl)-4-methyl-5-phenyloxazolidin-2-one 
• 1253909-49-7 (4S,5R)-3-((R)-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoyl)-4-methyl-5-phenyloxazolidin-2-one 
• 119818-40-5 (7Z,10Z,13Z,16Z,19Z)-ethyl docosa-7,10,13,16,19-pentaenoate 

Relevant articles and documents

A New Lipobetaine from the Red Alga Neodilsea yendoana

A new isosanoid lipobetaine has been isolated from a red alga and its structure has been determined to be (2S)-2--(8Z,11Z,14Z)-8,11,14-icosatrienoylamino>-5-trimethylammoniopentanoate, mainly on the basis of NMR spectral and chemical means.

NSAID derivatives of omega-3 polyunsaturated acids as gamma secretase modulators

The present invention relates to the NSAID derivatives of omega-3 fatty acids as gamma secretase modulators and their use in treating Alzheimer's disease, hypertriglyceridemia, and cardiovascular disease by reducing triglycerides, and for use as anti-inflammatory agents.

COMPOUND, COMPOSITION AND USES THEREOF

The compositions and compounds of formula I, formula II, formula III which includes a salt of polyunsaturated fatty acids in a molecular conjugate with amino acid isoleucine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection administration. Such compositions may be used to treatment of hyperglycemia, metabolic syndrome, diabetes, pre-diabetes, lowering triglycerides or its associated complications.